FDA warns Flextronics America, contract maker of FreeStyle Libre 3 glucose sensors in Austin, TX, over an unvalidated assembly step and weak corrective actions.
What happened
FDA inspected the Austin, TX plant from October 20 through October 30, 2025, and found problems in the step that assembles the sensor "pucks" for the FreeStyle Libre 3 continuous glucose monitor. The equipment that positions the circuit board had no defined settings or acceptable range, employees saw sensor damage, and maintenance logs since 2021 show repeated adjustments made without set specifications. FDA also found the corrective and preventive action (CAPA, the formal fix-and-prevent process) opened on 4/1/2025 did not identify the actions needed to stop the problem recurring.
What FDA found
The assembly step that positions the circuit board could not be fully checked by later testing, yet it was not validated with a high degree of assurance, and the equipment had no defined setting or acceptable range.
21 CFR 820.75(a)The installation qualification protocols and reports for the puck assembly machines set no specifications, setup activities, or acceptance criteria for aligning the part.
21 CFR 820.75(a)For over four years, repeated corrective maintenance was needed to adjust the tooling because parts were damaged or not picked up, and those adjustments were made with no established specifications or controls.
21 CFR 820.75(a)The CAPA opened on 4/1/2025 did not identify the actions needed to correct and prevent broken components and broken connections caused by the missing tooling specification, so maintenance requests to adjust the tooling continued after corrective actions began.
21 CFR 820.100(a)
What FDA wants
FDA tells the firm to reply in writing within 15 business days with the specific steps taken, supporting documentation, and a timetable for any actions still in progress. FDA also wants updates on the revalidation of the puck assembly process and on verification that the CAPA actually worked.
Who should pay attention
- brands that use this firm as a contract manufacturer of finished devices
- makers of wearable sensors and other devices with automated assembly lines
- quality teams that rely on supplier process validation and CAPA records
This is a summary. Read the original letter on fda.gov.